Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Compulsory License On Table In UK For Orkambi

Executive Summary

The UK government will consider all options to improve access to Vertex’s cystic fibrosis treatment, including compulsory licensing.

You may also be interested in...



Blog: No Easy Cure For Britain’s Brexit Madness

Prime Minister Boris Johnson has until 19 October to agree a deal, or otherwise must ask for another Brexit extension. But he's in no mood to follow the rules.

UK Opposition Party Wants Compulsory Licenses For ‘Extortionate’ Medicines

The UK’s main opposition party says it would use compulsory licensing to ensure access to “extortionately” priced medicines. Unsurprisingly, the responses are polarized.

£197m Payments Made Under New UK Pricing Scheme But Access Promises Still To Materialize

Payments have now been made under the UK’s 2019 pricing and access to branded medicines scheme, but industry will have to wait longer for promises on access to materialize.

Related Content

Topics

UsernamePublicRestriction

Register

PS125460

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel